LABELS · f778a079-d075-4205-bc94-8ec67e27c95e

CONEXXENCE

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-12-15
Captured: 2026-09-09T23:38:04.335995+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions ( 5.1 )] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions ( 5.1 )] . Prior to initiating Conexxence in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Conexxence in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.1 )]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Conexxence in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Conexxence in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 ), ( 5.1 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Conexxence is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Conexxence is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )]. 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Conexxence is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.2 )]. 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Conexxence is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.3 )] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Conexxence is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies ( 14.4 )] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Conexxence is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies ( 14.5 )] .

Full extracted label fields

application numbers

BLA761398

boxed warning exact

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions ( 5.1 )] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions ( 5.1 )] . Prior to initiating Conexxence in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Conexxence in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.1 )]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Conexxence in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Conexxence in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 ), ( 5.1 )

brand names

CONEXXENCE

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39a0a789-778f-4695-b3a9-61643e6396cd

generic names

DENOSUMAB

f778a079-d075-4205-bc94-8ec67e27c95e

indications and usage exact

1 INDICATIONS AND USAGE Conexxence is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Conexxence is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )]. 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Conexxence is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.2 )]. 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Conexxence is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.3 )] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Conexxence is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies ( 14.4 )] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Conexxence is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies ( 14.5 )] .

indications and usage tables exact

is original packager

true

manufacturer names

Fresenius Kabi USA, LLC

matched search terms

cancer

package ndcs

65219-668-01

product ndcs

65219-668

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2717531
2717538

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00800.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 370
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Conexxence is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 0

current approval status

not_reconciled

duplicate text group

dup-1da3199ca60286cb85ef

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-1e9fd8fbcdef412cfbdd

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 79
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 35

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 170
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Conexxence is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 )
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 451
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Conexxence is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastat
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 0

current approval status

not_reconciled

duplicate text group

dup-d05f66146c7bc78a44df

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-eedee18b3bd64cc2cb0d

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 79
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 35

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 251
end exclusive: true
exact text: to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 )
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 171

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · unclassified context

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 541
end exclusive: true
exact text: (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiv
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 52

current approval status

not_reconciled

duplicate text group

dup-dce16c9659f98b071dac

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-4cc87e1b86d70ea222fb

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 341
end exclusive: true
exact text: of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 )
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 252

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 677
end exclusive: true
exact text: gh risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 142

current approval status

not_reconciled

duplicate text group

dup-660449b6c7482c648f09

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-e5f2bb0ce4739164cb6f

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 79
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 35

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 477
end exclusive: true
exact text: to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 )
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 342

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · positive indication candidate

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 807
end exclusive: true
exact text: osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Conexxence is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, define
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 278

current approval status

not_reconciled

duplicate text group

dup-00061a35802494f130e2

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-ab79091d12369a9c32a7

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 79
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 35

qualifier mentions

context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
588
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
f778a079-d075-4205-bc94-8ec67e27c95e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start
545

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 607
end exclusive: true
exact text: to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 478

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 6 · positive indication candidate

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1173
end exclusive: true
exact text: ndrogen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Conexxence is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )]. 1.2 Treatment to Increase Bone Mass in Men wi
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 408

current approval status

not_reconciled

duplicate text group

dup-16676704243f773ca459

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-e9eabdc5da2bae5416d3

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 713
end exclusive: true
exact text: is indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 701

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 973
end exclusive: true
exact text: 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Conexxence is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 608

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1327
end exclusive: true
exact text: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )]. 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Conexxence is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of os
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 774

current approval status

not_reconciled

duplicate text group

dup-f8e6c8662282617c18e5

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-4dd742d3a48fa89c47cd

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1127
end exclusive: true
exact text: In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )].
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 974

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1705
end exclusive: true
exact text: rant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )]. 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Conexxence is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.2 )]. 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Conexxence is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiati
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 928

current approval status

not_reconciled

duplicate text group

dup-9703e2e74c7dfa83857d

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-7df5e7fd7bba286eae06

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 1212
end exclusive: true
exact text: is indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 1200

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1505
end exclusive: true
exact text: 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Conexxence is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.2 )].
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 1128

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2075
end exclusive: true
exact text: ed as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.2 )]. 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Conexxence is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 1306

current approval status

not_reconciled

duplicate text group

dup-942b2a75350db419edbc

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-684c18e260aec7d724cb

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 1582
end exclusive: true
exact text: is indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 1570

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1875
end exclusive: true
exact text: 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Conexxence is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 1506

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · risk or warning

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2303
end exclusive: true
exact text: cture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.3 )] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Conexxence is indicated as a treatment to increase bone mass in men at high risk for fracture receiving an
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 1676

current approval status

not_reconciled

duplicate text group

dup-d18a9eb25df90ac5e31e

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-91f452324fbf0ff40094

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2103
end exclusive: true
exact text: High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.3 )] .
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 1876

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2570
end exclusive: true
exact text: ined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.3 )] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Conexxence is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies ( 14.4 )] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 1904

current approval status

not_reconciled

duplicate text group

dup-d4e3b48d0c14de3f7e35

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-84dc5559eb4c3ff91fcc

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 2220
end exclusive: true
exact text: is indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 2208

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2370
end exclusive: true
exact text: 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Conexxence is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 2104

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · unclassified context

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2682
end exclusive: true
exact text: erapy for Prostate Cancer Conexxence is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies ( 14.4 )] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Conexxence is indicated as a treatment to increase bone mass in women at high risk for fracture re
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 2171

current approval status

not_reconciled

duplicate text group

dup-7c771467894df3955de7

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-d74a1fecc399a87c24cb

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2482
end exclusive: true
exact text: In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies ( 14.4 )] .
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 2371

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761398

brand names

CONEXXENCE

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2778
end exclusive: true
exact text: racture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies ( 14.4 )] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Conexxence is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies ( 14.5 )] .
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 2283

current approval status

not_reconciled

duplicate text group

dup-445e4aadee3218df4563

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-647b85055ce35b5c64db

label id

f778a079-d075-4205-bc94-8ec67e27c95e

positive predicate support span

end: 2607
end exclusive: true
exact text: is indicated
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 2595

qualifier mentions

context exact
1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Conexxence is indicated as a treatment to increa
kind
stage_or_setting
polarity
not_inferred
span
end
2572
end exclusive
true
exact text
Adjuvant Aromatase Inhibitor Therapy for Br
label id
f778a079-d075-4205-bc94-8ec67e27c95e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start
2529
context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies ( 14.5 )] .
kind
stage_or_setting
polarity
not_inferred
span
end
2733
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
f778a079-d075-4205-bc94-8ec67e27c95e
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start
2690

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2778
end exclusive: true
exact text: 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Conexxence is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies ( 14.5 )] .
label id: f778a079-d075-4205-bc94-8ec67e27c95e
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1b1d3e7c900d38914f42fe0af4e49a1537d9fde0c1d3d55e9e426410e5621041
start: 2483

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f778a079-d075-4205-bc94-8ec67e27c95e%22

spl effective date

2025-12-15

spl set id

39a0a789-778f-4695-b3a9-61643e6396cd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Preserved source evidence · Not medical advice